Costello Medical Consulting Ltd, Cambridge, Cambridgeshire, UK.
AstraZeneca, Cambridge, Cambridgeshire, UK.
Adv Ther. 2021 Jan;38(1):180-200. doi: 10.1007/s12325-020-01568-8. Epub 2020 Nov 24.
The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines recommend classifying patients by glomerular filtration rate (GFR) and albuminuria to predict chronic kidney disease (CKD) prognosis. The aim of this systematic review was to explore the epidemiological burden of CKD stratified by the KDIGO 2012 categories.
MEDLINE® and Embase were searched for observational studies of patients with CKD with results stratified according to the KDIGO 2012 classification. Investigated outcomes were prevalence, incidence, and risk factors and complications of CKD, including mortality.
The review included ten observational studies with 3033 to 46,949 participants, conducted in the USA, China, France, Italy and Spain. The most frequently reported outcome was the prevalence of CKD (GFR categories G3-5), ranging from 2% to 17%. Most participants were normoalbuminuric, with 0.4-3.2% macroalbuminuric, and most fell within the KDIGO 2012 low-risk or moderate-risk groups, with 0.9-5.6% in the high-risk and 0.3-4.8% in the very high-risk groups. Although scarce, data on the prevalence of comorbidities in CKD according to the KDIGO classification suggest that they increase with albuminuria severity.
Patients with CKD frequently have complications, but only a small proportion have severely increased albuminuria or fall within the KDIGO high-risk or very high-risk groups. These groups, however, are associated with the highest burden of disease, as comorbidities are more prevalent with increasing albuminuria severity. New studies framed by the KDIGO 2012 classification are needed to address key gaps in the understanding of CKD burden and outcomes.
肾脏疾病:改善全球预后组织(KDIGO)2012 指南建议根据肾小球滤过率(GFR)和白蛋白尿将患者分类,以预测慢性肾脏病(CKD)的预后。本系统评价的目的是探讨根据 KDIGO 2012 分类分层的 CKD 的流行病学负担。
检索 MEDLINE®和 Embase 中的观察性研究,这些研究的结果根据 KDIGO 2012 分类进行分层。调查的结果是 CKD 的患病率、发病率以及危险因素和并发症,包括死亡率。
本综述纳入了 10 项观察性研究,共有 3033 至 46949 名参与者,研究地点在美国、中国、法国、意大利和西班牙。报告最多的结果是 CKD(GFR 类别 G3-5)的患病率,范围为 2%至 17%。大多数参与者为非白蛋白尿患者,有 0.4-3.2%为大量白蛋白尿患者,大多数患者属于 KDIGO 2012 低风险或中风险组,高风险组有 0.9-5.6%,极高风险组有 0.3-4.8%。尽管数据很少,但根据 KDIGO 分类,CKD 合并症的患病率数据表明,随着白蛋白尿严重程度的增加,合并症的发生率也随之增加。
CKD 患者常伴有并发症,但只有一小部分患者有严重的白蛋白尿增加,或属于 KDIGO 高风险或极高风险组。然而,这些组与疾病负担最高相关,因为随着白蛋白尿严重程度的增加,合并症更为普遍。需要新的研究,这些研究应符合 KDIGO 2012 分类,以解决对 CKD 负担和结局的理解的关键差距。